EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Eblasakimab, a novel IL-13 receptor alpha 1 monoclonal antibody, blocks STAT6 phosphorylation with low dose in human volunteers

Ferda Cevikbas, Alison Ward, Carl Firth, Karen Veverka

Clinical Immunology · 2023

DOI: 10.1016/j.clim.2023.109677 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Immunology, 2023. Verfasst von Ferda Cevikbas und 3 weiteren Autor:innen. Beteiligte Einrichtung: ASLAN Pharmaceuticals, 400 Concar Drive, San Mateo, CA, USA. Electronic address: ferda.cevikbas@aslanpharma.com. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Interleukin-13. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Eblasakimab is a first-in-class monoclonal antibody under investigation for the treatment of atopic dermatitis (AD), which targets IL-13Rα1, a subunit of the Type 2 receptor complex. IL-13Rα1 stimulates phosphorylation of signal transducer and activator of transcription 6 (STAT6) to drive inflammation. This brief report investigates the mechanistic basis of eblasakimab and its effects on IL-13Rα1 signaling as part of a phase 1a, open-label, single ascending dose study. Single ascending doses of eblasakimab were administered by intravenous or subcutaneous injection to healthy male volunteers. The impact of eblasakimab on IL-13Rα1 receptor occupancy and STAT6 phosphorylation was assessed in participant blood monocytes. No serious treatment emergent adverse events were reported. Eblasakimab effectively blocked the IL-13Rα1 receptor and inhibited STAT6 phosphorylation with single doses of 3 mg/kg intravenously and 300 mg subcutaneously. Results support further clinical development of eblasakimab as a novel biologic for AD, with potential for 2- to 4-week dosing regimens.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, MonoclonalInterleukin-13HumansMaleReceptors, Interleukin-13PhosphorylationSTAT6 Transcription FactorInterleukin-13 Receptor alpha1 SubunitHealthy Volunteers

Stichwörter der Autor:innen

EblasakimabIL-13IL-4Inflammatory Th2 driven diseases

Substanzen

Receptors, Interleukin-13Antibodies, MonoclonalSTAT6 Transcription FactorInterleukin-13 Receptor alpha1 SubunitInterleukin-13STAT6 protein, human

Autor:innen und Institutionen

  • ASLAN Pharmaceuticals, 400 Concar Drive, San Mateo, CA, USA. Electronic address: ferda.cevikbas@aslanpharma.com.
  • ASLAN Pharmaceuticals, 400 Concar Drive, San Mateo, CA, USA.

Zitieren

APA

Cevikbas, F., Ward, A., Firth, C., & Veverka, K. (2023). Eblasakimab, a novel IL-13 receptor alpha 1 monoclonal antibody, blocks STAT6 phosphorylation with low dose in human volunteers. Clinical Immunology. https://doi.org/10.1016/j.clim.2023.109677

Vancouver

Cevikbas F, Ward A, Firth C, Veverka K. Eblasakimab, a novel IL-13 receptor alpha 1 monoclonal antibody, blocks STAT6 phosphorylation with low dose in human volunteers. Clinical Immunology. 2023. doi:10.1016/j.clim.2023.109677

BibTeX
@article{Cevikbas2023,
  author = {Cevikbas, Ferda and Ward, Alison and Firth, Carl and Veverka, Karen},
  title = {Eblasakimab, a novel IL-13 receptor alpha 1 monoclonal antibody, blocks STAT6 phosphorylation with low dose in human volunteers},
  journal = {Clinical Immunology},
  year = {2023},
  doi = {10.1016/j.clim.2023.109677}
}
Kostenlos starten →